Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas A Keks

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists|April 25, 2015
Vortioxetine: A multimodal antidepressant or another selective serotonin reuptake inhibitor?Nicholas A Keks, Judy Hope, Christine Culhane
International Psychogeriatrics|July 30, 2005
Transdermal estrogen patches for aggressive behavior in male patients with dementia: a randomized, controlled trialKathryn A Hall, Nicholas A Keks, Daniel W O'Connor
International Journal of Mental Health Nursing|November 15, 2002
Quality of life in schizophrenia: a review of the literature from 1995 to 2000Jaya Pinikahana, Brenda Happell, Judy Hope, et al.
Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists|March 17, 2023
Association between long-term use of prolactin-elevating antipsychotics in women and the risk of breast cancer: What are the clinical implications?Judith D Hope, Nicholas A Keks, David L Copolov
Issues in Mental Health Nursing|June 25, 2002
Exploring the complexity of compliance in schizophreniaJaya Pinikahana, Brenda Happell, Mark Taylor, et al.
The British Journal of Psychiatry : the Journal of Mental Science|August 2, 2007
Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label studyNicholas A Keks, Michael Ingham, Akbar Khan, et al.
Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists|September 11, 2018
Milnacipran: serotonin-noradrenaline reuptake inhibitor approved for fibromyalgia may be a useful antidepressantNicholas A Keks, Judy Hope, Simone Keogh, et al.
Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists|June 9, 2026
Prazosin for post-traumatic nightmares: A clinical audit in acute public psychiatric unit patientsConor Heeney, Samuel Rainbow, Anton Neville Isaacs, et al.
Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists|October 5, 2018
Characteristics, diagnoses, illness course and risk profiles of inpatients admitted for at least 21 days to an Australian private psychiatric hospitalNicholas A Keks, Judy Hope, William Pring, et al.
Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists|November 14, 2023
What clinicians need to know about intranasal esketamine for treatment-resistant depression?Judy Hope, David Copolov, John Tiller, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists|April 25, 2015
Vortioxetine: A multimodal antidepressant or another selective serotonin reuptake inhibitor?Nicholas A Keks, Judy Hope, Christine Culhane
International Psychogeriatrics|July 30, 2005
Transdermal estrogen patches for aggressive behavior in male patients with dementia: a randomized, controlled trialKathryn A Hall, Nicholas A Keks, Daniel W O'Connor
International Journal of Mental Health Nursing|November 15, 2002
Quality of life in schizophrenia: a review of the literature from 1995 to 2000Jaya Pinikahana, Brenda Happell, Judy Hope, et al.
Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists|March 17, 2023
Association between long-term use of prolactin-elevating antipsychotics in women and the risk of breast cancer: What are the clinical implications?Judith D Hope, Nicholas A Keks, David L Copolov
Issues in Mental Health Nursing|June 25, 2002
Exploring the complexity of compliance in schizophreniaJaya Pinikahana, Brenda Happell, Mark Taylor, et al.
The British Journal of Psychiatry : the Journal of Mental Science|August 2, 2007
Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label studyNicholas A Keks, Michael Ingham, Akbar Khan, et al.
Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists|September 11, 2018
Milnacipran: serotonin-noradrenaline reuptake inhibitor approved for fibromyalgia may be a useful antidepressantNicholas A Keks, Judy Hope, Simone Keogh, et al.
Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists|June 9, 2026
Prazosin for post-traumatic nightmares: A clinical audit in acute public psychiatric unit patientsConor Heeney, Samuel Rainbow, Anton Neville Isaacs, et al.
Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists|October 5, 2018
Characteristics, diagnoses, illness course and risk profiles of inpatients admitted for at least 21 days to an Australian private psychiatric hospitalNicholas A Keks, Judy Hope, William Pring, et al.
Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists|November 14, 2023
What clinicians need to know about intranasal esketamine for treatment-resistant depression?Judy Hope, David Copolov, John Tiller, et al.
Pageof 3